ZIVO BIOSCIENCE INC (OTCMKTS:ZIVO) Sellers Declined By 80% Their Shorts As Of Dec 8, 2018

Zivo Bioscience, Inc. (OTCMKTS:ZIVO) Corporate Logo

ZIVO BIOSCIENCE INC (OTCMKTS:ZIVO) reported a decrease of 80% in shares shorted. FINRA announced shares shorted of ZIVO’s total 700 shares. That’s 80% down from 3,500 shares.

The stock decreased 15.32% or $0.0228 during the last trading session, reaching $0.1261.Zivo Bioscience, Inc. has 101,468 shares volume, 76.24% up from normal. ZIVO is and has moved 0.00% since December 8, 2017. ZIVO underperformed the S&P 500 by 15.62%.

Zivo Bioscience, Inc., together with its subsidiaries, focuses on the research and identification of natural bioactive ingredients derived from its proprietary algal cultures.The firm is valued at $21.31 million. The firm intends to license and sell its natural bioactive ingredients to animal, food, dietary supplement, and medical food manufacturers; and license its bioactive molecules as lead compounds or templates for synthetic variants intended for therapeutic applications.Currently it has negative earnings. It is also involved in developing, manufacturing, marketing, and selling tests that allow individuals to optimize their health and identify future health risks, as well as provides insurers, employers, and healthcare providers with timely information to intervene with wellness programs, fitness regimes, or other preventative measures.

For more Zivo Bioscience, Inc. (OTCMKTS:ZIVO) news announced recently go to: Streetinsider.com, Digitaljournal.com, Digitaljournal.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “Form 8-K Zivo Bioscience, Inc. For: Nov 12 – StreetInsider.com” announced on November 14, 2018, “Zivo Bioscience Executes Letter Of Intent With Dr. Steven K. Grekin/Grekin Laboratories To Field Exclusive Line Of Beauty-From-Within Nutraceuticals – Press Release – Digital Journal” on December 03, 2018, “Zivo Claims Gras Status for its Proprietary Algal Biomass, Allowing Immediate Marketing of its Premiere Product as a Human Food Ingredient – Press Release – Digital Journal” with a publish date: November 12, 2018, “ZIVO Bioscience, Inc. Executes Debt Restructuring With Private Equity Firm HEP Investments, LLC – GlobeNewswire” and the last “Largest Shareholder of ZIVO Bioscience, Inc. to extend maturity date of its Convertible Debt – GlobeNewswire” with publication date: February 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.